Arkolith/Insider Trading/LGND/Form 4

Lamattina John L

DirectorLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Mar 31, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$434K
Net Open-Market Flow
-$434K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)2K$114.15$247K33K
Mar 6, 2026Sell(S)2K$200.76$434K31K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)2K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000036) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML